Table III.
Comparison of the serum levels of CEA, CA19-9 and CA72-4 with respect to different clinicopathological features in patients with gastric carcinoma.
| CEA | CA19-9 | CA72-4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ClinPath feature | n | Median | Z | P-value | Median | Z | P-value | Median | Z | P-value |
| Gender | −4.005 | <0.001 | 0.768 | 0.443 | 0.450 | 0.653 | ||||
| Male | 172 | 2.465 | 7.450 | 2.510 | ||||||
| Female | 44 | 1.175 | 12.000 | 2.575 | ||||||
| Age (years) | −0.440 | 0.660 | 0.459 | 0.647 | 0.001 | 0.999 | ||||
| ≤60 | 93 | 2.310 | 7.500 | 2.820 | ||||||
| >60 | 123 | 2.230 | 7.500 | 2.390 | ||||||
| Histology | −0.088 | 0.930 | −0.693 | 0.489 | −1.483 | 0.138 | ||||
| Diff | 52 | 2.270 | 7.450 | 1.970 | ||||||
| Undiff | 164 | 2.220 | 7.700 | 2.810 | ||||||
| T stage | −0.289 | 0.773 | −2.376 | 0.018 | −3.241 | 0.001 | ||||
| T1–2 | 53 | 2.230 | 6.600 | 1.530 | ||||||
| T3–4 | 140 | 2.170 | 9.700 | 2.745 | ||||||
| N stage | 0.860 | 0.390 | −1.607 | 0.108 | −1.868 | 0.062 | ||||
| N(−) | 71 | 2.230 | 6.600 | 1.880 | ||||||
| N(+) | 116 | 2.075 | 8.775 | 2.685 | ||||||
| M stage | 1.698 | 0.090 | 0.579 | 0.563 | 2.072 | 0.038 | ||||
| M0 | 193 | 2.210 | 7.400 | 2.320 | ||||||
| M1 | 23 | 4.130 | 11.200 | 6.290 | ||||||
| TNM stage | −0.011 | 0.991 | −2.721 | 0.007 | −3.883 | 0.0001 | ||||
| I/II | 100 | 2.370 | 6.600 | 1.795 | ||||||
| III/IV | 116 | 2.115 | 11.000 | 3.155 | ||||||
The non-parametric Wilcoxon two-sample test was used for the comparison of the differences in serum levels of the biomarkers.
a
Two-sided P-values. ClinPath, clinicopathological; Diff, differentiated; Undiff, undifferentiated; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.